Moderna: First participants in Phase 2/3 child vax study given doses

Moderna wrote on Twitter, "We just announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, our vaccine candidate against COVID-19, in children ages 6 months to less than 12 years."